Loading stock data…
Climb Bio (CLYM)
$15.90+0.38 (+2.45%)
Market ClosedLast close Sep 8
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Climb Bio, Inc. in the Healthcare sector is trading at $15.90 with a market capitalization of $640M. Wall Street consensus targets $26.64 (14 analysts), implying a +67.6% move over the next 12 months. The stock is currently near its 52-week high of $18.33, remaining 81.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +67.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.21M↑ | -$19.30M↓ | -$14.89M↓ | -$10.68M↑ | -$23.02M |
| Net Income | -$13.72M↑ | -$17.52M↓ | -$12.89M↓ | -$8.67M↑ | -$20.78M |
Peer Comparison
JNJUNHPFE
Fundamentals
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$639.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.65%
Volume
Today's trading volume
917,872
Recent News
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
Climb Bio reversed course downward Thursday despite potential "best-in-class" data for its experimental kidney disease treatment.
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio (NASDAQ:CLYM) presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China. The company said CLYM116 is designed to bind circulating APRIL, bring the tar
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
Climb Bio, Inc. (NASDAQ:CLYM) shares rose 17% on Thursday after the clinical-stage biotechnology company released Phase 1 trial data for CLYM116, its anti-APRIL monoclonal antibody being developed for IgA nephropathy.
Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
Climb Bio (CLYM) is back in focus after Beijing Mabworks Biotech began dosing the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, highlighting their joint development efforts. The clinical update arrives while Climb Bio’s share price has moved sharply, with a 1-month share price return of 38.94% and a 90-day share price return of 49.16%. This has contributed to a year-to-date share price return of 375.73% and a very large 1-year total shareholder return,...